The role of JAK/STAT signaling pathway and its inhibitors in diseases

P Xin, X Xu, C Deng, S Liu, Y Wang, X Zhou… - International …, 2020 - Elsevier
The JAK/STAT signaling pathway is an universally expressed intracellular signal
transduction pathway and involved in many crucial biological processes, including cell …

Tolerogenic dendritic cells in autoimmunity and inflammatory diseases

O Morante-Palacios, F Fondelli, E Ballestar… - Trends in …, 2021 - cell.com
Dendritic cells (DCs), the most efficient antigen-presenting cells, are necessary for the
effective activation of naïve T cells. DCs can also acquire tolerogenic functions in vivo and in …

Peptides, antibodies, peptide antibodies and more

N Trier, P Hansen, G Houen - International journal of molecular sciences, 2019 - mdpi.com
The applications of peptides and antibodies to multiple targets have emerged as powerful
tools in research, diagnostics, vaccine development, and therapeutics. Antibodies are …

[HTML][HTML] An overview of the history, pathophysiology, and pharmacological interventions of multiple sclerosis

IM Dighriri, AA Aldalbahi, F Albeladi, AA Tahiri… - Cureus, 2023 - ncbi.nlm.nih.gov
Multiple sclerosis (MS) is an immune-inflammatory disease that attacks and damages
myelinated axons in the central nervous system (CNS) and causes nontraumatic …

Progress in the Application of Drugs for the Treatment of Multiple Sclerosis

W Wei, D Ma, L Li, L Zhang - Frontiers in Pharmacology, 2021 - frontiersin.org
Multiple sclerosis (MS) is an autoimmune and chronic inflammatory demyelinating disease
of the central nervous system (CNS), which gives rise to focal lesion in CNS and cause …

The dual PDE7-GSK3β inhibitor, VP3. 15, as neuroprotective disease-modifying treatment in a model of primary progressive multiple sclerosis

R Benítez-Fernández, C Gil, C Guaza, L Mestre… - International Journal of …, 2022 - mdpi.com
Multiple sclerosis (MS) is a chronic, inflammatory, autoimmune and degenerative disease
with axonal damage and demyelination as its main features. Its dual neurological and …

Role of B cells and antibodies in multiple sclerosis

P Wanleenuwat, P Iwanowski - Multiple sclerosis and related disorders, 2019 - Elsevier
Multiple sclerosis (MS) is a chronically progressive auto-immune mediated inflammatory
demyelinating disease of the central nervous system (CNS) which manifests as disturbances …

CD19 cell count at baseline predicts B cell repopulation at 6 and 12 months in multiple sclerosis patients treated with ocrelizumab

G Abbadessa, G Miele, P Cavalla, P Valentino… - International Journal of …, 2021 - mdpi.com
Background: The kinetics of B cell repopulation in MS patients treated with Ocrelizumab is
highly variable, suggesting that a fixed dosage and time scheduling might be not optimal …

Response to oxidative stress of peripheral blood mononuclear cells from multiple sclerosis patients and healthy controls

C Pistono, MC Monti, C Boiocchi, FG Berzolari… - Cell Stress and …, 2020 - Springer
The complex scenario of multiple sclerosis (MS) pathology involves several mechanisms,
including oxidative stress response. The heat shock proteins (HSPs) are important for the …

Clinical and Immunological Impact of Ocrelizumab Extended Interval Dosing in Multiple Sclerosis: A Single-Center, Real-World Experience

M Nasello, V Zancan, V Rinaldi, A Marrone… - International Journal of …, 2024 - mdpi.com
Ocrelizumab (OCR), an anti-CD20 monoclonal antibody, is approved for treating relapsing
remitting (RR) and primary progressive (PP) multiple sclerosis (MS). The standard interval …